503536-73-0

Basic information

• Product Name: 5-(4-FLUOROPHENYL)-2-PYRIDINAMINE
• Synonyms: AKOS BAR-0872;5-(4-FLUOROPHENYL)-2-PYRIDINAMINE;2-Amino-5-(4-fluorophenyl)pyridine;5-(4-Fluorophenyl)pyridin-2-aMine
• CAS NO: 503536-73-0
• Molecular Formula: C₁₁H₉FN₂
• Molecular Weight: 188.2
• Mol File: 503536-73-0.mol

Chemical Properties

• Boiling Point: 320.611°C at 760 mmHg
• Flash Point: 147.7°C
• Appearance: /
• Density: 1.218
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: 2-8°C
• PKA: 6.19±0.26(Predicted)
• CAS DataBase Reference: 5-(4-FLUOROPHENYL)-2-PYRIDINAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-FLUOROPHENYL)-2-PYRIDINAMINE(503536-73-0)
• EPA Substance Registry System: 5-(4-FLUOROPHENYL)-2-PYRIDINAMINE(503536-73-0)

Safety Data

• Hazardous Substances Data: 503536-73-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-(4-FLUOROPHENYL)-2-PYRIDINAMINE is used as a building block for the synthesis of various drugs and biologically active compounds. Its structural attributes make it a key component in the development of novel pharmaceuticals.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5-(4-FLUOROPHENYL)-2-PYRIDINAMINE is utilized as a valuable tool for drug discovery. Its unique properties allow researchers to explore its potential in creating new drug candidates.
Used in Anti-Cancer Drug Development:
5-(4-FLUOROPHENYL)-2-PYRIDINAMINE has been studied for its potential as an anti-cancer agent. Its role in this application is attributed to its ability to be a precursor in the synthesis of novel drug candidates that target cancer cells.
Used as a Precursor in Synthesis:
As a precursor, 5-(4-FLUOROPHENYL)-2-PYRIDINAMINE is instrumental in the synthesis of new compounds that may exhibit therapeutic effects. Its presence in the molecular structure of these compounds can influence their pharmacological properties, making it an essential component in the development process.

InChI:InChI=1/C11H9FN2/c12-10-4-1-8(2-5-10)9-3-6-11(13)14-7-9/h1-7H,(H2,13,14)

Upstream product

• 20511-12-0 2-amino-5-iodopyridine 
• 1765-93-1 4-fluoroboronic acid 
• 504-29-0 2-aminopyridine 
• 1072-98-6 5-chloro-2-pyridylamine 
• 71-36-3 butan-1-ol 
• 1072-97-5 5-bromo-2-pyridylamine 

Downstream Products

• 779203-65-5 ethyl-[5-(4-fluoro-phenyl)-pyridin-2-yl]-amine 
• 924279-80-1 2-amino-3-bromo-5-(4-fluorophenyl)pyridine 

Relevant articles and documents

Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agent

In order to identify anti-tubercular agents with a novel scaffold, commercial libraries of small organic compounds were screened against a fluorescent strain of Mycobacterium tuberculosis H37Rv, using a dual phenotypic assay. Compounds were assessed again

Recyclable Pd/CuFe2O4 nanowires: A highly active catalyst for C-C couplings and synthesis of benzofuran derivatives

Pd/CuFe2O4 nanowire-catalyzed cross coupling transformations are described. Notably, these reactions showed excellent functional group tolerance. Further, the protocol is applied to a one-pot synthesis of benzofurans via a Sonogashira coupling and intramolecular etherification sequence. The catalyst was reused and found to maintain its activity and stability.

Synthesis and evaluation of the anticoccidial activity of trifluoropyrido[1,2-a]pyrimidin-2-one derivatives

Screening of our chemical library to discover new molecules exhibiting in vitro activity against the invasion of host cells by Eimeria tenella revealed a lead compound with an IC50 of 15 μM. Structure-activity relationship studies were conducted with 34 newly synthesized compounds to identify more active molecules and enhance in vitro activity against the parasite. Four compounds were more effective in inhibiting MDBK cell invasion in vitro than the lead compound.

WNT PATHWAY MODULATORS

The present invention relates to dihydropyrazolo[l,5-a]pyrimidine compounds of formula I, defined herein, as WNT pathways modulators, processes for making them, and pharmaceutical compositions comprising them. Methods of treatment of conditions mediated by WNT pathway signalling including cancer, fibrosis, stem cell and diabetic retinopathy, rheumatoid arthritis, psoriasis and myocardial infarction, comprising the compounds of formula I are also provided.

Peptide deformylase inhibitors

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhi-bition of bacterial peptide deformylase (PDF) activity

Aryl pyridines and methods of their use

Aryl pyridines, compositions comprising them, and methods of their use for the treatment, prevention and management of a variety of diseases and disorders are disclosed.

New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes

Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.

Compounds that modulate PPAR activity and methods of preparation

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.